Niagen Bioscience
NAGE
123 hedge funds and large institutions have $119M invested in Niagen Bioscience in 2024 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 34 increasing their positions, 26 reducing their positions, and 7 closing their positions.
644% more call options, than puts
Call options by funds: $1.53M | Put options by funds: $206K
486% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 7
85% more capital invested
Capital invested by funds: $64.3M → $119M (+$55M)
35% more funds holding
Funds holding: 91 → 123 (+32)
31% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 26
6.23% more ownership
Funds ownership: 23.21% → 29.44% (+6.2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$5.24M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$2.69M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$1.9M |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$1.81M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$1.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tieton Capital Management
Yakima,
Washington
|
-$2.01M |
| 2 |
WG
Winton Group
London,
United Kingdom
|
-$870K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$494K |
| 4 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$338K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$223K |
NAGE Hedge Fund Activity: Q4 2024 in Review
123 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q4 2024, worth a combined $119M — up 85% from $64.3M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new NAGE positions and 7 closed out — a net gain of 34 holders — while 34 added to existing stakes and 26 trimmed.
The largest buyer was D.E. Shaw & Co, adding an estimated $5.24M. The largest seller was Tieton Capital Management, cutting an estimated $2.01M.
- 123 institutional investors held Niagen Bioscience (NAGE) as of Q4 2024, up from 91 in Q3 2024.
- Funds reported $119M of Niagen Bioscience stock for Q4 2024, up 85% quarter-over-quarter.
- 41 funds opened new Niagen Bioscience positions in Q4 2024 and 7 closed out, a net change of +34 holders.
- The largest Niagen Bioscience buyer in Q4 2024 was D.E. Shaw & Co, an estimated $5.24M added.
- The largest Niagen Bioscience seller in Q4 2024 was Tieton Capital Management, an estimated $2.01M sold.
Based on aggregated 13F filings for Q4 2024.